Physician profile
Brian Wong
NPI 1053706267
$2,774.87
in general payments reported to CMS, 2019-2025
29 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $991 · 2024: $1,130 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,774.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $422.40 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Jazz Pharmaceuticals INC. | $412.76 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $333.88 | 2023-2025 | Ultomiris |
| Corium, LLC | $201.62 | 2023-2025 | Azstarys |
| Neurelis, INC. | $181.28 | 2023-2025 | Valtoco |
| Lilly USA, LLC | $121.77 | 2024 | Amyvid, Kisunla |
| Sumitomo Pharma America, INC. | $117.49 | 2023-2024 | Aptiom |
| Biogen, INC. | $105.34 | 2023-2025 | Spinraza, Skyclarys, Qalsody |
| Axsome Therapeutics, INC. | $100.40 | 2023-2025 | Sunosi |
| Teva Pharmaceuticals USA, INC. | $84.35 | 2024-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Tanabe Pharma America, INC. | $82.24 | 2024-2025 | Radicava |
| Alnylam Pharmaceuticals INC. | $60.27 | 2023-2025 | Amvuttra |
| Idorsia Pharmaceuticals US INC | $57.18 | 2023 | Quviviq |
| Inspire Medical Systems, INC. | $55.05 | 2025 | Inspire |
| Argenx US, INC. | $53.50 | 2025 | Vyvgart Hytrulo, Vyvgart |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $50.25 | 2023-2025 | Botox |
| Acadia Pharmaceuticals INC | $49.85 | 2023-2024 | Daybue |
| Xeris Pharmaceuticals, INC. | $45.69 | 2023-2024 | Keveyis |
| Avadel Cns Pharmaceuticals, LLC | $38.10 | 2025 | Lumryz |
| Amneal Pharmaceuticals LLC | $27.62 | 2024 | Rytary |
| Sk Life Science, INC. | $24.91 | 2025 | |
| Aquestive Therapeutics, INC. | $24.85 | 2024 | |
| Kyowa Kirin, INC. | $21.91 | 2024 | Nourianz |
| Itf Therapeutics LLC | $21.63 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $17.34 | 2024 | |
| Scilex Pharmaceuticals INC. | $17.28 | 2023 | Ztlido |
| Astrazeneca Pharmaceuticals LP | $15.56 | 2024 | Wainua |
| Cranial Technologies, INC | $15.28 | 2023 | Doc Band |
| Biomarin Pharmaceutical INC. | $15.07 | 2024 | Brineura |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.